知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

137 条记录 (耗时 0.035 秒)

    Activatable Anti-CTLA-4 Antibodies and Uses Thereof
    63.
    发明申请
    Activatable Anti-CTLA-4 Antibodies and Uses Thereof 有权

    公开(公告)号：US20220089734A1

    公开(公告)日：2022-03-24

    申请号：US17399729

    申请日：2021-08-11

    申请人： Bristol-Myers Squibb Company ,  CytomX Therapeutics, Inc.

    发明人： Kimberly Ann TIPTON ,  James William WEST ,  Shrikant DESHPANDE ,  John J. ENGLEHARDT

    IPC分类号： C07K16/28 ,  A61K39/395

    摘要： Provided herein are activatable anti-human CTLA-4 antibodies comprising a heavy chain comprising a VH domain and a light chain comprising a masking moiety (MM), a cleavable moiety (CM), and a VL domain. Such activatable anti-human CTLA-4 antibodies have CTLA-4 binding activity in the tumor microenvironment, where the masking moiety is removed by proteolytic cleavage of the cleavable moiety by tumor-specific proteases, but exhibit greatly reduced binding to CTLA-4 outside the tumor. In this way, the activatable anti-human CTLA-4 antibodies of the present invention retain anti-tumor activity while reducing the side effects associated with anti-CTLA-4 activity outside the tumor.

    Activatable anti-CTLA-4 antibodies and uses thereof
    64.
    发明授权
    Activatable anti-CTLA-4 antibodies and uses thereof 有权

    公开(公告)号：US11117968B2

    公开(公告)日：2021-09-14

    申请号：US16347522

    申请日：2017-11-02

    申请人： Bristol-Myers Squibb Company ,  CytomX Therapeutics, Inc.

    发明人： Kimberly Ann Tipton ,  James William West ,  Shrikant Deshpande ,  John J. Englehardt

    IPC分类号： C07K16/28 ,  A61K39/395

    摘要： Provided herein are activatable anti-human CTLA-4 antibodies comprising a heavy chain comprising a VH domain and a light chain comprising a masking moiety (MM), a cleavable moiety (CM), and a VL domain. Such activatable anti-human CTLA-4 antibodies have CTLA-4 binding activity in the tumor microenvironment, where the masking moiety is removed by proteolytic cleavage of the cleavable moiety by tumor-specific proteases, but exhibit greatly reduced binding to CTLA-4 outside the tumor. In this way, the activatable anti-human CTLA-4 antibodies of the present invention retain anti-tumor activity while reducing the side effects associated with anti-CTLA-4 activity outside the tumor.

    Cleavage-activatable interferon-alpha proprotein
    68.
    发明授权
    Cleavage-activatable interferon-alpha proprotein 有权

    公开(公告)号：US10513549B2

    公开(公告)日：2019-12-24

    申请号：US15589464

    申请日：2017-05-08

    申请人： CytomX Therapeutics, Inc.

    发明人： Nancy E. Stagliano ,  James W. West ,  Kathryn Kamath ,  Paul H. Bessette ,  Jason G Sagert

    IPC分类号： C07K14/56 ,  C07K14/00 ,  C07K14/555 ,  C07K19/00 ,  G01N33/68 ,  C07K14/705 ,  A61K47/65 ,  A61K38/00 ,  C07K14/565 ,  C07K14/57 ,  C07K16/00 ,  C12N15/10 ,  A61K47/64

    摘要： The present disclosure provides for proprotein and activatable proprotein compositions. A proprotein contains a functional protein (i.e. a full length protein or functional fragment thereof) which is coupled to a peptide mask that inhibits the binding of the functional protein to its target or binding partner. An activatable proprotein contains a functional protein coupled to a peptide mask, and further coupled to an activatable linker, wherein in an non-activated state, the peptide mask inhibits binding of the functional protein to its target or binding partner and in an activated state the peptide mask does not inhibit binding of the functional protein to its target or binding partner. Proproteins can provide for reduced toxicity and adverse side effects that could otherwise result from binding of a functional protein at non-treatment sites if it were not inhibited from binding its binding partner. Proproteins can further provide improved biodistribution characteristics. Proproteins containing a peptide mask can display a longer in vivo or serum half-life than the corresponding functional protein not containing a peptide mask. The disclosure further provides methods of screening for, making, and using these proproteins.

    Antibodies specific for urokinase-type plasminogen activator and methods of use thereof for treating cancer
    69.
    发明授权
    Antibodies specific for urokinase-type plasminogen activator and methods of use thereof for treating cancer 有权

    公开(公告)号：US10239954B2

    公开(公告)日：2019-03-26

    申请号：US15608729

    申请日：2017-05-30

    申请人： The Regents of the University of California ,  CytomX Therapeutics, Inc.

    发明人： Natalia Sevillano ,  Aaron M. Lebeau ,  Daniel Robert Hostetter ,  Charles S. Craik

    IPC分类号： A61K49/00 ,  A61K51/10 ,  C07K16/40

    摘要： The present disclosure relates to antibodies specific for urokinase-type plasminogen activator (uPA). According to certain embodiments, the anti-uPA antibody specifically binds to the active form of uPA. In certain aspects, the anti-uPA antibody that specifically binds to active uPA binds specifically to the active form of human uPA (e.g., the antibody does not cross-react with active forms of uPA from non-human organisms). In certain aspects, an anti-uPA antibody of the present disclosure competes for specific binding to uPA with plasminogen activator inhibitor type 1 (PAI-1), where binding of the antibody to uPA results in internalization of a complex that includes the antibody, uPA, and urokinase-type plasminogen activator receptor (uPAR). Also provided are antibodies that specifically bind to uPA and compete for binding to uPA with a synthetic ligand of uPA. The disclosure also provides anti-uPA antibody conjugates and compositions (e.g., pharmaceutical formulations) comprising the antibodies and/or conjugates. Methods and kits related to the anti-uPA antibodies, conjugates, or formulations including the antibodies and/or conjugates are also provided.